Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia
- PMID: 18766970
- DOI: 10.1080/10428190802146078
Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia
Abstract
We evaluated patients with newly diagnosed ALL treated at the Cleveland Clinic during the years 1996 through 2005. Cox proportional hazards analysis was used to identify univariate and multivariate correlates of complete remission, overall survival and progression-free survival. On univariate analysis, significant prognostic factors included: age at diagnosis (per 10-year increase), poor risk cytogenetics, time to white blood count recovery, and time from induction chemotherapy (IC) to post-remission therapy (PRT). In patients age <60 years without poor risk cytogenetics, time from IC to PRT (per week increase) was a significant prognostic factor by multivariate analysis and was associated with a decreased progression-free survival [HR 1.27, CI (1.04-1.55), p = 0.019] and decreased overall survival [HR 1.34, CI (1.08-1.67), p = 0.009]. Delayed time from IC to PRT (> or =6.6 weeks) was associated with a statistically worse progression-free and overall survival.
Similar articles
-
Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period.Leukemia. 2001 Dec;15(12):1811-22. doi: 10.1038/sj.leu.2402289. Leukemia. 2001. PMID: 11753600
-
Pretreatment grade 4 thrombocytopenia is an independent prognostic factor in adult acute lymphoblastic leukemia: an extended analysis of a single-center retrospective study.Hematology. 2021 Dec;26(1):26-30. doi: 10.1080/16078454.2020.1856512. Hematology. 2021. PMID: 33357100
-
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.Am J Hematol. 2016 Jun;91(4):385-9. doi: 10.1002/ajh.24296. Epub 2016 Feb 9. Am J Hematol. 2016. PMID: 26800008 Free PMC article.
-
Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.Haematologica. 2002 Feb;87(2):154-66. Haematologica. 2002. PMID: 11836166 Clinical Trial.
-
Prognostic factors in adult acute lymphoblastic leukemia.Hematology. 2003 Aug;8(4):233-42. doi: 10.1080/1024533031000153621. Hematology. 2003. PMID: 12911941 Review.
Cited by
-
Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.Biol Blood Marrow Transplant. 2018 May;24(5):945-955. doi: 10.1016/j.bbmt.2017.12.784. Epub 2017 Dec 21. Biol Blood Marrow Transplant. 2018. PMID: 29275139 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources